Loading…
Loading…
Early aggressive intervention, DAS28-guided therapy escalation, and joint preservation
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterised by symmetric polyarthritis that, if inadequately treated, leads to irreversible joint destruction, disability, and increased cardiovascular mortality. The treat-to-target (T2T) strategy — endorsed by EULAR, ACR, and APLAR — mandates achieving remission or low disease activity within six months through rapid DMARD initiation and protocolised escalation. At Dr. Shree Narayan's clinic, DAS28-ESR or DAS28-CRP is measured at every visit, methotrexate is initiated within the diagnostic window, and biologic or targeted synthetic DMARDs are escalated at three-month intervals when targets are not met. This approach reduces radiographic progression by up to 70% compared with conventional symptom-driven management.
Kathmandu Neurology Clinic & Cognitive Center
Authored and reviewed by Dr. Shree Narayan Yadav (MBBS (KU), MD-Internal Medicine (NAMS), MSc Clinical Rheumatology (USW, UK), NMC 14227). Evidence-based, no fabricated outcomes.
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterised by symmetric polyarthritis that, if inadequately treated, leads to irreversible joint destruction, disability, and increased cardiovascular mortality. The treat-to-target (T2T) strategy — endorsed by EULAR, ACR, and APLAR — mandates achieving remission or low disease activity within six months through rapid DMARD initiation and protocolised escalation. At Dr. Shree Narayan's clinic, DAS28-ESR or DAS28-CRP is measured at every visit, methotrexate is initiated within the diagnostic window, and biologic or targeted synthetic DMARDs are escalated at three-month intervals when targets are not met. This approach reduces radiographic progression by up to 70% compared with conventional symptom-driven management.
Reviewed by Dr. Shree Narayan Yadav, MBBS, MD, MSc — Consultant Physician & Joint and Autoimmune Disease Specialist (NMC 14227), Kathmandu Neurology Clinic. For evaluation, book an appointment.
RA synovitis begins when citrullinated self-antigens activate autoreactive T and B cells in genetically susceptible individuals carrying shared epitope HLA-DRB1 alleles. The resulting immune complex deposition triggers synovial fibroblast proliferation, pannus formation, and release of matrix metalloproteinases that erode cartilage and bone. Importantly, a window of opportunity exists in the first 3 to 6 months of symptoms during which aggressive DMARD therapy can fundamentally alter the disease trajectory, reducing the likelihood of future biologic need by up to 40% and preventing erosions that accumulate irreversibly thereafter.
The T2T protocol begins with methotrexate (15 mg/week oral, titrated to 25 mg/week over 8 weeks) combined with folic acid supplementation. DAS28 is assessed every 4 to 6 weeks during escalation and every 3 months thereafter. If the target (DAS28 less than 3.2 or remission less than 2.6) is not met within 3 months, the protocol escalates to combination conventional DMARD therapy (methotrexate plus sulfasalazine plus hydroxychloroquine). If targets remain unmet after 6 months of combination therapy, biologic DMARDs (anti-TNF, abatacept, or tocilizumab) or JAK inhibitors (tofacitinib, baricitinib) are initiated.
Guidelines referenced:
Regular laboratory monitoring is essential for patients on DMARD therapy. Methotrexate requires baseline and then every 1 to 3 months FBC, LFTs, and renal function. Hepatotoxicity, myelosuppression, and pulmonary toxicity are the most serious adverse events. Hydroxychloroquine requires annual ophthalmological screening after 5 years of use (or sooner with additional risk factors) to detect retinal toxicity. Biologic therapy necessitates tuberculosis screening (quantiferon or tuberculin skin test), hepatitis B and C serology, and vaccination review before initiation.
Smolen JS et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological DMARDs: 2022 update. Ann Rheum DisFraenkel L et al. 2021 ACR guideline for the treatment of rheumatoid arthritis. Arthritis RheumatolAletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria. Ann Rheum DisContent on this website is for general educational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not a substitute for evaluation by a qualified healthcare professional. Always seek the advice of your physician or other qualified provider with any questions regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read on this website. In case of a medical emergency, contact emergency services immediately. No doctor–patient relationship is established by use of this site or by contacting the clinic through the site.